Unichem Laboratories has entered into a settlement agreement with Eli Lilly & Company and ICOS Corporation.The agreement is for resolving their patent litigation regarding generic tadalafil, used for treating erectile dysfunction.

In a BSE filing it stated, the company , “has entered into a settlement agreement with Eli Lilly & Company and ICOS Corporation to resolve their patent litigation in the US District Court, for District of New Jersey regarding Unichem’s Abbreviated New Drug Application for generic tadalafil (CialisB).”

Further, under the agreement, Unichem expects to launch its generic tadalafil product in the US on or not before March 26, 2019 under certain circumstances.

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week